Methylphenidate

Amber-G

Brand Name(s):

Indication:Counteracting sedation with opioids in palliative care (off-label use)

Rationale:

Considered:Aug-15

Review Date:Jul-20

Comments:
Methylphenidate is indicatedfor use in opioid-related drowsiness, and depression where prognosis <2-4 weeks. The dose should be stable before asking the GP to prescribe and is usually within the range of 5mg BD to 20mg BD, where the second daily dose is given around lunchtime. DBHFT Aug 2015